Clinical trials
Pulmonary Fibrosis clinical trials
Below are recruiting pulmonary fibrosis clinical trials, each written for real people, not researchers. We’re tracking 143 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06951217RecruitingPhase 2
Long-term safety study of an inhaled drug for lung scarring
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
Birmingham, AlabamaAges 18 years+ - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
Los Angeles, CaliforniaAges 40 years+ - NCT07251725Recruiting
Genetic study of family-linked lung scarring
This study looks for genetic causes of pulmonary fibrosis that runs in families. You and your affected family member(s) would provide blood samples and health info to help researchers understand why lung scarring happens.
Pavia, LombardyAges 18 years+ - NCT07516951RecruitingPhase 2
Study of zampilimab for idiopathic pulmonary fibrosis
This trial tests an investigational drug called zampilimab for people with idiopathic pulmonary fibrosis (IPF). It aims to find a safe and effective dose that may slow lung function decline.
SkopjeAges 40 years+ - NCT03478553Recruiting
Study of genes in people with pulmonary fibrosis
This study looks at genetic (inherited) factors related to pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF). It may help researchers understand why some families are more affected and could guide future testing or treatments.
Aurora, ColoradoAges 18 years+ - NCT03535545RecruitingPhase 1
PET-MRI imaging test in lung cancer and lung disease
This Phase 1 study tests a radioactive imaging agent to help doctors see disease activity in the lungs using PET/MRI scans. It includes healthy volunteers and people with lung cancer, idiopathic pulmonary fibrosis, lung transplant–related lung problems, or certain medication-related lung inflammation.
Boston, MassachusettsAges 18–80 - NCT04362644RecruitingPhase 1
Imaging agent study for idiopathic pulmonary fibrosis lung scarring
This Phase 1 study tests a specialized imaging agent that can help show differences (heterogeneity) in lung scarring in idiopathic pulmonary fibrosis (IPF). It’s mainly about safety and whether the imaging works for people with certain genetic and lung-function features.
Birmingham, AlabamaAges 40–85 - NCT05842681Recruiting
Azithromycin for early worsening of idiopathic pulmonary fibrosis
This trial studies whether adding azithromycin to standard care can help people whose idiopathic pulmonary fibrosis is starting to flare up (worsen) in the early stages. It’s mainly for adults who are not very sick and cannot require intensive breathing support.
AsyutAges 18–80 - NCT05975983RecruitingPhase 2
Oral treatment test for idiopathic pulmonary fibrosis
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
Birmingham, AlabamaAges 40 years+ - NCT06323876Recruiting
Using CT scans to personalize treatment for pulmonary fibrosis
This study uses detailed CT scans to find better ways to treat idiopathic pulmonary fibrosis (IPF). It may help doctors choose the right treatment for each person.
Charlottesville, VirginiaAges 40–101 - NCT06567717RecruitingPhase 2
Zinc and vitamin B3 supplement for IPF
This trial tests whether adding zinc and nicotinamide riboside (a vitamin B3-like supplement) to standard IPF treatment can help improve lung function. It is for people with IPF who are already seeing a lung doctor and live in certain states.
Los Angeles, CaliforniaAges 50 years+ - NCT06747923RecruitingPhase 2
SB17170 for Idiopathic Pulmonary Fibrosis (IPF)
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
GoyangAges 40 years+ - NCT06853145RecruitingEarly Phase 1
Using a special MRI scan to study lung disease in IPF
This trial uses an advanced MRI technique with a special gas (hyperpolarized xenon-129) to look at lung function in people with idiopathic pulmonary fibrosis (IPF). It may help doctors better understand how the disease affects your lungs and could lead to improved care.
Charlottesville, VirginiaAges 18 years+ - NCT07121413RecruitingPhase 2
Testing SV001 for Idiopathic Pulmonary Fibrosis
This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.
ChengduAges 40 years+ - NCT07230288RecruitingPhase 2
Study of ABBV-142 for Idiopathic Pulmonary Fibrosis
This trial is testing a new antibody drug, ABBV-142, to see if it can reduce disease activity in adults with idiopathic pulmonary fibrosis (IPF). It may help if your IPF was diagnosed within the last 7 years and you meet certain health criteria.
Dothan, AlabamaAges 40 years+ - NCT00258570Recruiting
Study genetics in idiopathic pulmonary fibrosis patients
This study looks at genetic differences in people with idiopathic pulmonary fibrosis (a lung scarring condition with no known cause). It may help researchers understand what influences the disease and guide future treatment options.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07447102RecruitingPhase 2
Study of BC006 for Idiopathic Pulmonary Fibrosis
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
Shanghai, Shanghai MunicipalityAges 40 years+ - NCT06629623Enrolling by invitation
IPF diagnosis, treatment and quality of life study
This study looks at how idiopathic pulmonary fibrosis (IPF) is diagnosed and treated, and how it affects patients' daily lives. It aims to learn from both patients and their doctors to improve care.
Beijing, Beijing MunicipalityAges Any age - NCT06967805RecruitingPhase 2
Study of MTX-463 for Idiopathic Pulmonary Fibrosis
This trial tests an experimental drug called MTX-463 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if targeting a protein called WISP1 can slow lung scarring and help you breathe better.
Birmingham, AlabamaAges 40 years+ - NCT07723872Recruiting
Finger vs. earlobe oxygen test during a 6-minute walk
This study compares oxygen levels measured at the finger versus the earlobe during a 6-minute walk test for people with interstitial lung disease. It helps find the most accurate way to monitor your oxygen during exercise.
Granollers, SpainAges 18 years+ - NCT07284602RecruitingPhase 3
Comparing a new drug to pirfenidone for lung scarring
This trial tests a new medicine, LYT-100 (deupirfenidone), against the standard drug pirfenidone for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the new drug works better or has fewer side effects.
Palm Spring, CaliforniaAges 40 years+ - NCT04160715Recruiting
Registry for people with idiopathic pulmonary fibrosis in Korea
This study is a registry that collects health information from people diagnosed with idiopathic pulmonary fibrosis (IPF). It may help researchers better understand IPF and how it changes over time, even if it doesn’t involve a new medication.
Seongnam-siAges 30–100 - NCT05571059RecruitingPhase 2
Ifetroban pills for idiopathic pulmonary fibrosis
This trial studies ifetroban, an oral medicine, in people with idiopathic pulmonary fibrosis (IPF) to see if it improves outcomes and is safe. It may be an option if your IPF is confirmed on lung scans and your lung function tests meet the trial thresholds.
La Mesa, CaliforniaAges 40 years+ - NCT06125327RecruitingPhase 2/Phase 3
SC1011 for idiopathic pulmonary fibrosis (IPF)
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
Beijing, Beijing MunicipalityAges 40–80
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary fibrosis?
- Yes. Clin2 currently lists 143 recruiting pulmonary fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.